J&J buys Intra-Cellular in $14.6B deal, delving into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of…

A promising schizophrenia drug showed mixed results. What does that mean for patients?

Some people who took a new schizophrenia drug for a year improved with only a few…